Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients

被引：25

作者：

Dosanjh, A ^{[1
]}

机构：

[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2006年 / 536卷 / 03期

关键词：

pirfenidone; chronic rejection; transplantation;

D O I：

10.1016/j.ejphar.2006.03.007

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans after human lung transplantation. AJRCCM. 166, 440-444.]. This review summarizes the literature to date on Pirfenidone in the setting of transplantation, and those studies pertinent to the mechanisms of organ rejection and possible use of Pirfenidone in transplantation patients. (c) 2006 Elsevier B.V. All rights reserved.

引用

收藏

页码：219 / 222

页数：4

相关论文

共 21 条

[1]

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].

Azuma, A ;

Nukiwa, T ;

Tsuboi, E ;

Suga, M ;

Abe, S ;

Nakata, K ;

Taguchi, Y ;

Nagai, S ;

Itoh, H ;

Ohi, M ;

Sato, A ;

Kudoh, S ;

Raghu, G .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047

[2]

Bergmann M, 1998, SCAND CARDIOVASC J, V32, P97

[3]

The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model [J].

Brook, NR ;

Waller, JR ;

Bicknell, GR ;

Nicholson, ML .

TRANSPLANTATION PROCEEDINGS, 2005, 37 (01) :130-133

[4]

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity [J].

Brook, NR ;

Waller, JR ;

Bicknell, GR ;

Nicholson, ML .

JOURNAL OF SURGICAL RESEARCH, 2005, 125 (02) :137-143

[5]

Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection [J].

Dosanjh, A ;

Ikonen, T ;

Wan, B ;

Morris, RE .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2002, 15 (05) :433-437

[6]

Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis [J].

Dosanjh, AK ;

Wan, B ;

Throndset, W ;

Sherwood, S ;

Morris, RE .

TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :1910-1911

[7]

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome [J].

Gahl, WA ;

Brantly, M ;

Troendle, J ;

Avila, NA ;

Padua, A ;

Montalvo, C ;

Cardona, H ;

Calis, KA ;

Gochuico, B .

MOLECULAR GENETICS AND METABOLISM, 2002, 76 (03) :234-242

[8]

Giri Shri N., 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P169

[9]

Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts [J].

Kaneko, M ;

Inoue, H ;

Nakazawa, R ;

Azuma, N ;

Suzuki, M ;

Yamauchi, S ;

Margolin, SB ;

Tsubota, K ;

Saito, I .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 113 (01) :72-76

[10]

Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model [J].

Liu, HZ ;

Drew, P ;

Cheng, YP ;

Visner, GA .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (03) :852-858